亨廷顿病在亚洲的流行:一个系统的审查和元分析
Basavaraja Papanna1, Carlo Lazzari2, Marco Rabottini3
1Department of General Adult Psychiatry, Essex Partnership University Foundation Trust, Essex, United Kingdom.
Rivista di psichiatria
|February 16, 2024
概括
亨廷顿病 (HD) 对亚洲人群的影响较少于西方人群,在中国患病率最低. 这种差异可能是由于亚洲人群的社会耻辱,缺乏测试和遗传因素.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 遗传学 是一个遗传学.
背景情况:
- 流行病学研究表明,与西方人群相比,亚洲人群的亨廷顿病 (HD) 患病率较低.
- 本系统性审查旨在比较HD对亚洲人口的影响.
研究的目的:
- 系统地审查和分析有关亚洲亨廷顿病 (HD) 患病率的流行病学研究.
- 为了比较亚洲人口和西方国家的HD流行率.
主要方法:
- 使用Embase,Medline和PsychInfo数据库对亚洲疾病流行率的原始文章和评论进行系统审查.
- 对患病率的元分析,计算每10万人口的点患病率 (PP) 以95%信心区间 (CI95) 计算.
主要成果:
- 中东地区的HD点患病率最高 (PP=4.0,CI95=2.90-5.30).
- 中国人口的流行率最低 (PP=0.25,CI95=0.16-0.36).
- 亚洲的总体流行率是PP=0.70 (CI95=0.44-1.0),明显低于欧洲的PP=1.00 (CI95=0.82-1.19).
结论:
- 亨廷顿病对亚洲人口的影响比欧洲人口的影响要小.
- 患病率较低的潜在原因包括社会耻辱,对婚姻影响的恐惧以及对遗传/神经测试的限制.
- 遗传因素,如特定的CAG重复子组和C单元组,可能导致亚洲人与白人相比更低的HD倾向.
相关概念视频
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
Single Nucleotide Polymorphisms-SNPs
15.1K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.1K
Hazard Ratio
122
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
122


